Esperion Therapeutics, Inc. (LON:0IIM)

Market Cap	597.03M +93.2%
Revenue (ttm)	226.01M +2.8%
Net Income	-78.73M
EPS	-0.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	9.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,858
Average Volume	43,739
Open	3.455
Previous Close	3.411
Day's Range	3.410 - 3.495
52-Week Range	0.700 - 4.170
Beta	1.04
RSI	49.97
Earnings Date	Mar 3, 2026

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2008
• Employees: 304
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IIM

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Financial numbers in USD